HC Wainwright Has Positive Outlook for NAMS FY2026 Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Equities researchers at HC Wainwright increased their FY2026 EPS estimates for shares of NewAmsterdam Pharma in a research report issued on Friday, November 6th. HC Wainwright analyst L. Egana-Gorrono now expects that the company will post earnings of ($1.50) per share for the year, up from their previous forecast of ($1.82). HC Wainwright currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.62) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2026 earnings at ($0.43) EPS, FY2027 earnings at ($1.48) EPS, FY2028 earnings at $1.30 EPS, FY2029 earnings at $5.72 EPS and FY2030 earnings at $7.70 EPS.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.33. The business had revenue of $19.16 million during the quarter, compared to analysts’ expectations of $8.82 million. NewAmsterdam Pharma had a negative net margin of 789.95% and a negative return on equity of 31.04%.

Several other equities research analysts also recently issued reports on NAMS. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Sunday, November 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Needham & Company LLC cut their price objective on NewAmsterdam Pharma from $48.00 to $46.00 and set a “buy” rating on the stock in a report on Thursday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, October 15th. Finally, Royal Bank Of Canada decreased their price objective on NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating for the company in a research report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, NewAmsterdam Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $48.70.

NewAmsterdam Pharma Trading Up 0.5%

NAMS stock opened at $19.00 on Tuesday. The business’s 50-day moving average price is $21.96 and its two-hundred day moving average price is $29.45. The firm has a market cap of $2.27 billion, a PE ratio of -11.24 and a beta of 0.15. NewAmsterdam Pharma has a 1-year low of $17.90 and a 1-year high of $42.21.

Insider Buying and Selling

In related news, insider Johannes Kastelein sold 50,246 shares of the firm’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $25.03, for a total transaction of $1,257,657.38. Following the sale, the insider directly owned 69,302 shares in the company, valued at $1,734,629.06. This trade represents a 42.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael Davidson acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average cost of $22.65 per share, for a total transaction of $226,500.00. Following the completion of the transaction, the chief executive officer directly owned 792,923 shares in the company, valued at $17,959,705.95. This represents a 1.28% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 176,846 shares of company stock worth $4,661,919 over the last ninety days. Company insiders own 12.74% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

Institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. grew its holdings in shares of NewAmsterdam Pharma by 6.8% during the second quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock worth $613,033,000 after buying an additional 1,145,128 shares in the last quarter. Maverick Capital Ltd. raised its position in NewAmsterdam Pharma by 15.4% in the 1st quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company’s stock valued at $69,987,000 after buying an additional 292,176 shares during the last quarter. Bank of America Corp DE lifted its stake in NewAmsterdam Pharma by 84.4% in the 1st quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock valued at $27,115,000 after acquiring an additional 387,698 shares in the last quarter. SEB Asset Management AB bought a new stake in NewAmsterdam Pharma in the 1st quarter valued at approximately $8,728,000. Finally, Stempoint Capital LP lifted its stake in NewAmsterdam Pharma by 147.1% in the 1st quarter. Stempoint Capital LP now owns 180,658 shares of the company’s stock valued at $5,783,000 after acquiring an additional 107,552 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company’s lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol.

NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment.